Necrosulfonamide-d4 is intended for use as an internal standard for the quantification of necrosulfonamide by GC- or LC-MS. Necrosulfonamide is an inhibitor of necroptosis, apoptosis, and pyroptosis.1,2 It inhibits IL-8-induced increases in receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, mixed lineage kinase domain-like protein (MLKL), caspase-3, and caspase-8 levels, as well as IL-8-induced necroptosis and apoptosis in isolated human nucleus pulposus cells.1 Necrosulfonamide binds to gasdermin D and inhibits NLRP3- and pyrin-mediated pyroptosis in mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 5 µM.2 In vivo, necrosulfonamide (20 mg/kg) increases survival in a mouse model of LPS-induced sepsis. It also improves motor function and reduces spinal edema in a mouse model of surgically induced spinal cord injury (SCI).3
1.Zhang, Q.-X., Guo, D., Wang, F.-C., et al.Necrosulfonamide (NSA) protects intervertebral disc degeneration via necroptosis and apoptosis inhibitionEur. Rev. Med. Pharmacol. Sci.24(5)2683-2691(2020) 2.Rathkey, J.K., Zhao, J., Liu, Z., et al.Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsisSci. Immunol.3(26)eaat2738(2018) 3.Jiao, J., Wang, Y., Ren, P., et al.Necrosulfonamide ameliorates neurological impairment in spinal cord injury by improving antioxidative capacityFront. Pharmacol.101538(2020)